Raj Chakraborty, Hematologist, Oncologist, Clinical Researcher at Herbert Irving Comprehensive Cancer Center, and Assistant Professor at Columbia University Irving Medical Center, shared a post on X:
“Registrational trials of Bispecific Antibodies in Multiple Myeloma ought to be designed as fixed-duration going forward. Continuous BsAb treatment until progression is unsustainable, especially in earlier lines of treatment.
FDA Oncology should require sponsors to design either a fixed-duration or include a fixed-duration comparator arm in registrational trials. While the infection rate drops after 1st 6-9 cycles, it never plateaus with continuous therapy!”
Other articles about Multiple Myeloma on OncoDaily.